HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: clinchem.2004.032227v1 50/8/1344    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (107) Citing Articles via Google Scholar Google Scholar Articles by Poynard, T. Articles by Ratziu, V. Search for Related Content PubMed PubMed Citation Articles by Poynard, T. Articles by Ratziu, V. Related Collections Evidence Based Laboratory Medicine and Test Utilization Proteomics and Protein Markers

Prospective Analysis of Discordant Results between Biochemical Markers and Biopsy in Patients with Chronic Hepatitis C

¹ Service d’Hépato-Gastroentérologie, Groupe Hospitalier Pitié-Salpêtrière, Université Paris VI, Paris, France. ² Laboratoire de Biochimie, ³ Service d’Anatomie Pathologique, and ⁴ Laboratoire de Virologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.

^aAddress correspondence to this author at: Service d’Hépato-Gastroentérologie, Groupe Hospitalier Pitié-Salpêtrière, 47 Boulevard de l’Hôpital, 75651 Paris Cedex 13, France. Fax 33-1-4216-1427; e-mail tpoynard{at}teaser.fr.

Background: The FibroTest and ActiTest are noninvasive biochemical markers of liver injury that are intended for use as alternatives to liver biopsy in patients with chronic hepatitis C. The aims of this study were to assess the quality of biopsy and the prevalence of discordances between biopsy and markers, to identify factors associated with discordances, and to attribute these discordances to either markers or biopsy failure.

Methods: Fibrosis stage and activity grade were prospectively assessed on the same day by a liver biopsy and by markers. On the basis of risk factors for failure and independent endpoints, discordance was classified as being attributable to biopsy or to markers.

Results: Only 74 of 537 patients (14%) had a biopsy size 25 mm. Discordance was observed in 154 of 537 patients (29%), including 16% for fibrosis staging and 17% for activity grading. Steatosis, an inflammatory profile, and biopsy size were associated with discordance. Discordance was attributable to failure of markers in 13 patients (2.4%) and to biopsy failure in 97 (18%; P <0.001 vs Fibrotest and Actitest), and was nonattributable in 44 patients (8.2%). The most frequent failures attributable to markers were false negatives (1.3%) attributable to inflammation. The most frequent failures attributable to biopsy were false negatives of activity grading (10.1%) and of fibrosis staging (4.5%), both associated with smaller biopsy size and steatosis. False positives of fibrosis staging (3.5%) were associated with fragmented biopsies.

Conclusion: In this series, the size of liver biopsy is adequate in only a minor proportion (14%) of patients with chronic hepatitis C. When biopsy and marker results are discordant, a reason can be identified in more than two-thirds of cases and, in those cases, biopsy failure is >7 times more common than diagnostic failure of markers.

The following articles in journals at HighWire Press have cited this article:

				M. Friedrich-Rust, K. Wunder, S. Kriener, F. Sotoudeh, S. Richter, J. Bojunga, E. Herrmann, T. Poynard, C. F. Dietrich, J. Vermehren, et al. Liver Fibrosis in Viral Hepatitis: Noninvasive Assessment with Acoustic Radiation Force Impulse Imaging versus Transient Elastography Radiology, August 1, 2009; 252(2): 595 - 604. [Abstract] [Full Text] [PDF]

				D. Vanderschaeghe, W. Laroy, E. Sablon, P. Halfon, A. Van Hecke, J. Delanghe, and N. Callewaert GlycoFibroTest Is a Highly Performant Liver Fibrosis Biomarker Derived from DNA Sequencer-based Serum Protein Glycomics Mol. Cell. Proteomics, May 1, 2009; 8(5): 986 - 994. [Abstract] [Full Text] [PDF]

				M. Friedrich-Rust, C. Koch, A. Rentzsch, C. Sarrazin, P. Schwarz, E. Herrmann, A. Lindinger, U. Sarrazin, T. Poynard, H.-J. Schafers, et al. Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 560 - 567. [Abstract] [Full Text] [PDF]

				T. Poynard, P. Halfon, L. Castera, M. Munteanu, F. Imbert-Bismut, V. Ratziu, Y. Benhamou, M. Bourliere, V. de Ledinghen, and FibroPaca Group Standardization of ROC Curve Areas for Diagnostic Evaluation of Liver Fibrosis Markers Based on Prevalences of Fibrosis Stages Clin. Chem., September 1, 2007; 53(9): 1615 - 1622. [Abstract] [Full Text] [PDF]

				Y. Ngo, M. Munteanu, D. Messous, F. Charlotte, F. Imbert-Bismut, D. Thabut, P. Lebray, V. Thibault, Y. Benhamou, J. Moussalli, et al. A Prospective Analysis of the Prognostic Value of Biomarkers (FibroTest) in Patients with Chronic Hepatitis C Clin. Chem., October 1, 2006; 52(10): 1887 - 1896. [Abstract] [Full Text] [PDF]

				J Macias, J A Giron-Gonzalez, M Gonzalez-Serrano, D Merino, P Cano, J A Mira, A Arizcorreta-Yarza, J Ruiz-Morales, J M Lomas-Cabeza, J A Garcia-Garcia, et al. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes Gut, March 1, 2006; 55(3): 409 - 414. [Abstract] [Full Text] [PDF]

				D. R. Dufour Assessment of Liver Fibrosis: Can Serum Become the Sample of Choice? Clin. Chem., October 1, 2005; 51(10): 1763 - 1764. [Full Text] [PDF]

				N. H. Afdhal Biopsy or Biomarkers: Is There a Gold Standard for Diagnosis of Liver Fibrosis? Clin. Chem., August 1, 2004; 50(8): 1299 - 1300. [Full Text] [PDF]